ReviewNature reviews. Clinical oncology2014
Translational research in oncology--10 years of progress and future prospects.
Review in Nature reviews. Clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed.
- Commentary: Making Patient Data Count-Opportunities and Challenges for Open Science in Clinical Psychology.Journal of clinical psychology · 2026Article
- Oligometastatic Bladder Cancer: Current Definitions, Diagnostic Challenges, and Evolving Therapeutic Strategies.Cancers · 2026Review
- Research training, barriers, and career development needs of early-career investigators in oncology: an EORTC survey-based study.ESMO gastrointestinal oncology · 2025Article
- Cancer genomics and bioinformatics in Latin American countries: applications, challenges, and perspectives.Frontiers in oncology · 2025Review
- The increasing role of the allergist in the management of infusion reactions at the Oncology Infusion Center.Frontiers in allergy · 2024Article
- Integrating frontiers: a holistic, quantum and evolutionary approach to conquering cancer through systems biology and multidisciplinary synergy.Frontiers in oncology · 2024Review
- Polydatin enhances oxaliplatin-induced cell death by activating NOX5-ROS-mediated DNA damage and ER stress in colon cancer cells.Frontiers in pharmacology · 2024Article
- Predictive value of an ultrasound-based radiomics model for central lymph node metastasis of papillary thyroid carcinoma.International journal of medical sciences · 2024Article
- Severe testing with high-dimensional omics data for enhancing biomedical scientific discovery.NPJ systems biology and applications · 2022Article
- The Radiosensitivity Index Gene Signature Identifies Distinct Tumor Immune Microenvironment Characteristics Associated With Susceptibility to Radiation Therapy.International journal of radiation oncology, biology, physics · 2022Article
- Gynecologic Cancer, Cancer Stem Cells, and Possible Targeted Therapies.Frontiers in pharmacology · 2022Review
- COVID-19, Social Justice, and Clinical Cancer Research.Journal of the National Cancer Institute · 2021Article
- [Research progress of radiomics with artificial intelligence in precise diagnosis and treatment of hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2020Article
- Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing.Nature communications · 2020Article
- Implementing a clinical cutting-edge and decision-making activity: an ethnographic teamwork approach to a molecular tumorboard.BMC health services research · 2020Article
- Patient-Derived Tumor Xenograft Models: Toward the Establishment of Precision Cancer Medicine.Journal of personalized medicine · 2020Review
- The emerging roles of WBP2 oncogene in human cancers.Oncogene · 2020Review
- Predicting the likelihood of early recurrence based on mRNA sequencing of pituitary adenomas.Gland surgery · 2019Article
- [Quantitative analysis of hepatocellular carcinomas pathological grading in non-contrast magnetic resonance images].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2019Article
- "Somatic" and "pathogenic" - is the classification strategy applicable in times of large-scale sequencing?Haematologica · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
International efforts to sequence the genomes of various human cancers have been broadly deployed in drug discovery programmes. Diagnostic tests that predict the value of the molecularly targeted anticancer agents used in such programmes are conceived and validated in parallel with new small-molecule treatments and immunotherapies. This approach has been aided by better preclinical cancer models; an enhanced appreciation of the complex interactions that exist between tumour cells and their microenvironment; the elucidation of interactions between many of the genetic drivers of cancer, including oncogenes and tumour suppressors; and recent insights into the genetic heterogeneity of human tumours made possible by extraordinary improvements in DNA-sequencing techniques. These advances are being employed in the first generation of genomic clinical trials that will examine the feasibility of matching a broad range of systemic therapies to specific molecular tumour characteristics. More-extensive molecular characterization of tumours and their supporting matrices are anticipated to become standard aspects of oncological practice, permitting continuous molecular re-evaluations of human malignancies on a patient-by-patient and treatment-by-treatment basis. We review selected developments in translational cancer biology, diagnostics, and therapeutics that have occurred over the past decade and offer our thoughts on future prospects for the next few years.
Indexed as
Identifiers
25286976What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.